Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LTO1 pseudogene 1 (LTO1P1, also known as ORAOV1P1) is a human pseudogene. Pseudogenes are non-functional DNA segments that resemble functional genes but typically do not encode proteins due to disablements such as premature stop codons or frameshifts[7]. LTO1P1 shares sequence homology with ORAOV1 ("Oral cancer overexpressed 1"), a gene known for its frequent overexpression in oral and other squamous cell carcinomas, implicating the functional gene (but not its pseudogene) in tumor growth, apoptosis, cell cycle regulation, and angiogenesis[2][4]. Pseudogenes like LTO1P1 can sometimes regulate gene expression via RNA mechanisms but, for this pseudogene, there is no established functional or therapeutic relevance. LTO1P1 is not considered a therapeutic target, and no interacting drugs, disease roles, or biomarker status are attributed to it[3][5][7].
Not applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LTO1 pseudogene 1 (LTO1P1).